Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Advances Two First-in-Class Clinical DART® Molecules

First patient dosed with MGD013 (PD-1 x LAG-3 DART) IND submitted for MGD014 (HIV x CD3 DART) NIAID exercises option to advance MGD014 and develop second HIV-directed DART molecule ...
August 31, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen

ROCKVILLE, MD, Aug. 31, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
August 30, 2017 17:00 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Three Investor Conferences in September

ROCKVILLE, MD, Aug. 30, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
August 09, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Wedbush PacGrow Healthcare Conference

ROCKVILLE, MD, Aug. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
August 02, 2017 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results

ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
July 26, 2017 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call

ROCKVILLE, MD, July 26, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 2, 2017, the Company will release its financial results for the quarter...
July 17, 2017 09:20 ET | Source: MacroGenics, Inc.

Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017

ROCKVILLE, MD, July 17, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
June 17, 2017 02:15 ET | Source: MacroGenics, Inc.

MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)

ROCKVILLE, MD, June 17, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
May 03, 2017 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results

ROCKVILLE, Md., May 03, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
April 27, 2017 07:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Registered Direct Offering of Common Stock

Rockville, MD, April 27, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...